Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Intellia Therapeutics's NTLA-2001?
NTLA-2001 is a gene therapy commercialized by Intellia Therapeutics, with a leading Phase III program in Familial Amyloid Cardiomyopathy. According...
NTLA-2001 by Regeneron Pharmaceuticals for Familial Amyloid Cardiomyopathy: Likelihood of Approval
NTLA-2001 is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Familial Amyloid Cardiomyopathy. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Intellia Therapeutics's NTLA-2001?
NTLA-2001 is a gene therapy commercialized by Intellia Therapeutics, with a leading Phase III program in Familial Amyloid Cardiomyopathy. According...